243 related articles for article (PubMed ID: 18393831)
1. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
2. MVA and NYVAC as vaccines against emergent infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Perdiguero B; Esteban M
Curr Gene Ther; 2011 Jun; 11(3):189-217. PubMed ID: 21453284
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
4. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
Karkhanis LU; Ross TM
Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
[TBL] [Abstract][Full Text] [Related]
5. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
Verheust C; Goossens M; Pauwels K; Breyer D
Vaccine; 2012 Mar; 30(16):2623-32. PubMed ID: 22342706
[TBL] [Abstract][Full Text] [Related]
6. Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J; Esteban M
Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
[TBL] [Abstract][Full Text] [Related]
7. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
[TBL] [Abstract][Full Text] [Related]
8. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
9. Innate immune recognition of poxviral vaccine vectors.
Lousberg EL; Diener KR; Brown MP; Hayball JD
Expert Rev Vaccines; 2011 Oct; 10(10):1435-49. PubMed ID: 21988308
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
[TBL] [Abstract][Full Text] [Related]
11. New viral vectors for infectious diseases and cancer.
Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
[TBL] [Abstract][Full Text] [Related]
12. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
Esteban M
Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
[TBL] [Abstract][Full Text] [Related]
13. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
14. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
[TBL] [Abstract][Full Text] [Related]
15. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
Quakkelaar ED; Redeker A; Haddad EK; Harari A; McCaughey SM; Duhen T; Filali-Mouhim A; Goulet JP; Loof NM; Ossendorp F; Perdiguero B; Heinen P; Gomez CE; Kibler KV; Koelle DM; Sékaly RP; Sallusto F; Lanzavecchia A; Pantaleo G; Esteban M; Tartaglia J; Jacobs BL; Melief CJ
PLoS One; 2011 Feb; 6(2):e16819. PubMed ID: 21347234
[TBL] [Abstract][Full Text] [Related]
16. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
17. Poxvirus vaccines for cancer and HIV therapy.
Essajee S; Kaufman HL
Expert Opin Biol Ther; 2004 Apr; 4(4):575-88. PubMed ID: 15102606
[TBL] [Abstract][Full Text] [Related]
18. Recombinant poxviruses as mucosal vaccine vectors.
Gherardi MM; Esteban M
J Gen Virol; 2005 Nov; 86(Pt 11):2925-2936. PubMed ID: 16227213
[TBL] [Abstract][Full Text] [Related]
19. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
[TBL] [Abstract][Full Text] [Related]
20. Recombinant MVA vaccines: dispelling the myths.
Cottingham MG; Carroll MW
Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
